The General Hospital Corporation

Dana-farber-cancer Institute Inc.

Juan Guillermo Paez

Daniel Arie Haber

Pasi Antero Janne

Matthew Meyerson

Thomas J Lynch

Raffaella Sordella

William R Sellers

Jeffrey E Settleman

Daphne Winifred Bell

Bruce E Johnson

Bruce E Johnston

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Growing community of inventors

Boston, MA, United States of America

Juan Guillermo Paez